Pfizer, Inc. (PFE)
$18.25
-0.34 (-1.83%)
| CAPS Rating |
|
|---|---|
| Open | $18.08 |
| Previous Close | $18.59 |
| Daily Range | $18.00 - $18.41 |
| 52-Week Range | $11.62 - $18.90 |
| Market Cap | $147.27B |
| P/E Ratio | 15.44 |
| Dividend (Yield) | 0.64 (3.40%) |
| Volume | 22,824,184 |
| Average Daily Volume | 62,201,000 |
PFE
VS S&P 500 (SPY)
How do you think PFE will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
PFE Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
PFE News and Commentary
- This Week's 5 Dumbest Stock Moves – The Motley Fool
- Dubai Jitters Rattle Drug Stocks; QLT Gains – SmartMoney
- Discover This Secret Weapon for Your Portfolio – The Motley Fool
- Second Round Bids For Ratiopharm Due By Dec 4 - Sources – SmartMoney
- 3 China Profit Plays – The Motley Fool
- T.V ads for drugs don't work,study finds – Blog at The Motley Fool
- Still Enjoying Those Acquisitions, Pfizer? – The Motley Fool
- Novartis Didn't Know JAK, Until Now – The Motley Fool
- A Schizophrenic Move by Merck? – The Motley Fool
- Catch a high-flying fund - up 56% – CNN Money
- Health perks for the unemployed – CNN Money
- Pfizer says to expand R&D in central, western China – Reuters
- 4 Platform Drugmakers to Invest In – The Motley Fool
- Big Winners for Small Investors – The Motley Fool
- Hedge funds boost stock exposure in 3rd qtr -Goldman – Reuters
- UK's NICE Rejects Roche's Avastin In Bowel Cancer – SmartMoney
- Pfizer told to pay $28 mln damages in Prempro case – Reuters
- The Side Effect of Developing Obesity Drugs – The Motley Fool
- Pa. Jury Orders Pfizer To Pay $28 Million In Punitive Damages – SmartMoney
- CNBC on Pfizer, Inc. – Ockham-RazorWire
RSS Headlines
Fool UK
